Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

14.73 -11.80 (-44.46%)

Streaming Delayed Price Updated: 2:12 PM EDT, Sep 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	19,936,072
Open	14.00
Bid (Size)	14.73 (100)
Ask (Size)	14.74 (2,100)
Prev. Close	26.53
Today's Range	13.81 - 15.00
52wk Range	18.29 - 39.89
Shares Outstanding	70,814,462
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Thursday's session: top gainers and losers ↗

Today 12:30 EDT

Via Chartmill

Gapping stocks in Thursday's session ↗

Today 10:30 EDT

Via Chartmill

Performance

YTD	-37.6%	-37.6%
1 Month	-41.1%	-41.1%
3 Month	-34.2%	-34.2%
6 Month	-32.4%	-32.4%
1 Year	-54.0%	-54.0%

More News

Wondering what's happening in today's pre-market session? ↗

Today 8:30 EDT

Via Chartmill

These stocks are moving in today's after hours session ↗

September 02, 2026

Via Chartmill

Ultragenyx (NASDAQ:RARE) Q2 Beats Estimates, Reaffirms Guidance as Shares Rise ↗

August 04, 2026

Via Chartmill

Ultragenyx Pharma (NASDAQ:RARE) Dips After Q1 Miss as Pipeline Catalysts Loom ↗

May 05, 2026

Via Chartmill

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

September 02, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease

September 01, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 25, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy ↗

August 20, 2026

Via MarketBeat

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

August 19, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx (RARE) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights ↗

August 04, 2026

Via MarketBeat

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

August 04, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

July 28, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 24, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

July 08, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

June 23, 2026

From Calidi Biotherapeutics, Inc

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 19, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

June 03, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗

May 30, 2026

Via The Motley Fool

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 22, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

May 06, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

May 05, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

April 29, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?

Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.

What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?

Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?

The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market

What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?

The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 14.73

When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?

The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 09/03/26 02:12 PM ET

What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?

The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.04B

How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?

Ultragenyx Pharmaceutical Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.